Our platform POB
has been created by an
interdisciplinary group of clinicians
with a deep interest in perioperative
bleeding management. High academic
standards of our educational platform
POB are ensured by our board
members. The founder members are
anaesthesiologists, a haematologist
and lab physician, and an
anaesthesiologist and
pharmacologist. It took one year from
the initial spark in summer 2008 to
the launch in summer 2009.
Board members
 |
Prof. Dr. Sibylle Kozek-Langenecker
Professor and Chairwoman, Department of Anaesthesia and Intensive Care,
Evangelisches
Krankenhaus Vienna, Vienna Austria |
She is Professor of Anaesthesiology and President elect of the
Austrian Society of
Anesthesiology, Resuscitation and Intensive Care (ÖGARI), former
chairwoman of the Task Force on Perioperative Coagulation of the
ÖGARI, chairwoman of the subcommittee 6 Transfusion and Haemostasis of
the European
Society of Anesthesiology (ESA), and member of the scientific
committee of the Network for the Advancement of Transfusion
Alternatives (NATA). She is an examiner for the Austrian
examination for anaesthesiologists and has a keen interest in the
training of undergraduates and postgraduates in anaesthesiology at the Vienna Medical University.
Her
main area of research is praeoperative evaluation and optimisation,
platelet function monitoring, intraoperative point-of-care (POC)
coagulation monitoring and the POC-guided treatment algorithm, and
fluid management. She has published widely on these subjects and she
serves on the editorial board of Anesthesiology Research & Practice
(Section Transfusion), Anästhesie, Intensivmedizin, Notfallmedizin und
Schmerz AINS and as a reviewer for many journals in the areas of
anaesthesiology and haemostasis.
Disclosure statement: Dr. Kozek has disclosed that she has received
honoraria as a speaker and research support from the following
commercial organisations: Astra Zeneca, Baxter, B.Braun, Biotest, CSL
Behring, Dynabyte, Ekomed, Fresenius Kabi, GlaxoSmithKline, Mitsubishi
Pharma, NovoNordisk, Octapharma, Pentapharm.
 |
Prof. Hugh C. Hemmings, Jr., M.D., Ph.D.
Departments of Anesthesiology and Pharmacology
Weill Medical College of Cornell University, New York, U.S.A. |
Dr. Hemmings's research interests include the
neuropharmacology of general anaesthetics and
neuronal cell signalling. His clinical interests
include thoracic anaesthesia, neuroanaesthesia
and novel approaches to analgesia. He is
co-editor of the textbook "Foundations of
Anesthesia". He is an Editor of Anesthesiology
and of the British Journal of Anaesthesia.
Conflicts of Interest: Dr. Hemmings has served
as a consultant for Abbott, Biowave, Cadence,
CSL Behring and Skye-Pharma, and has received
research support from Biowave and NIH.
 |
Prof. Dr. Charles Marc Samama
Professor and Chairman, Department of Anaesthesiology and Intensive Care
Hotel Dieu University Hospital, Paris, France
|
Dr. Samama is board certified to practice anaesthesiology and
intensive care medicine. He holds a Master's degree in Haemostasis and
Thrombosis and his PhD dissertation was based on an experimental model
of thrombosis in the pig. He heads a laboratory in the INSERM 765
research unit and, over many years, developed an experimental model of
arterial thrombosis and bleeding in the rabbit.
Dr. Samama is the past-president of the Scientific Committee of
the French Society of
Anaesthesiology and Intensive Care (SFAR). He worked as an active
member of subcommittee 6 Transfusion and Haemostasis of
the European
Society of Anesthesiologists (ESA) and is also a member of the
International Society of Thrombosis and Haemostasis (ISTH).
He also serves as a consultant for a number of professional journals in anaesthesiology, haemostasis and drug safety, and has published more than 100 peer-reviewed articles and anaesthesiology reviews. He has directed the French Guidelines on Perioperative Venous Thromboembolism (VTE) Prophylaxis and worked as a co-author in the VTE prophylaxis section of the 8th ACCP conference.
Dr. Samama received unrestricted grants for experimental animal studies and medical writing from LFB, NovoNordisk and CSL Behring. He received consultant fees from Sanofi-Aventis, GSK, Pfizer and BMS, and he was on the advisory board of Bayer and Curacyte.
 |
Prof. Dr. Donat R. Spahn
Institute of Anaesthesiology
University Hospital Zurich, Zurich, Switzerland
|
Dr. Spahn is Professor and Chairman of the Institute of Anaesthesiology at the University Hospital Zurich, Switzerland. He received his medical degrees from Zurich University and undertook his residency in anaesthesia and surgery in Aarau, Baden an Zurich, Switzerland. He trained in Cardiac Anaesthesia in the Department of Anaesthesiology, Division of Cardiac Anaesthesia, in the Heart Centre at Duke, Duke University Medical Centre, Durham, North Carolina.
Dr. Spahn's current areas of interest include perioperative risk assessment and cardioprotection, praeconditioning and organ protection, pulmonary and renal physiology, oxygen transport, blood transfusion and alternatives including praeoperative anaemia treatment, artificial oxygen carriers, anaemia tolerance, crystalloid and colloid therapy, blood coagulation, physiology of cardiopulmonary bypass, perioperative monitoring and pain. In addition, he is heavily involved in postgraduate training and (CME-credited) education. His clinical interests are in the perioperative treatment of high risk surgical patients and the implementation of Patient Blood Management. He has served on the editorial board of several scientific journals and has published over 290 articles in well-known international scientific journals.
Conflicts of Interest: Dr. Spahn's academic department is currently receiving grant support from the University of Zurich, the Research Award Centre for Zurich Integrative Human Physiology, the Swiss National Science Foundation, the Swiss Foundation for Anesthesia Research, the European Society of Anaesthesiology (ESA), the Swiss Society of Anaesthesiology and Reanimation (SGAR), the Gebert Ruef Foundation, the Swiss Life Foundation, the Olga Mayenfisch Foundation, Abbott AG, Switzerland and B. Braun, Switzerland, UBS, Switzerland, Stiftung für Staublungenforschung, Switzerland. Dr. Spahn is chairman of the ABC Faculty and a member of the ABC Trauma Faculty which are both managed by Thomson Physicians World GmbH, Mannheim, Germany and sponsored by an unrestricted educational grant from Novo Nordisk A/S, Bagsvärd, Denmark. In addition, in the past 5 years, Dr. Spahn has received honoraria or travel support for consulting or lecturing from the following companies: Abbott AG, Baar, Switzerland, Alliance Pharmaceutical Corp., San Diego, California, USA, AstraZeneca AG, Zug, Switzerland, Bayer (Schweiz) AG, Zürich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany, Fresenius SE, Bad Homburg v.d.H., Germany, Galenica AG, Bern, Switzerland (including Vifor SA, Villars-sur-Glâne, Switzerland), GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany, Janssen-Cilag AG, Baar, Switzerland, Novo Nordisk A/S, Bagsvärd, Denmark, Octapharma AG, Lachen, Switzerland, Organon AG, Pfäffikon/SZ, Switzerland, Oxygen Biotherapeutics, Costa Mesa, CA, and Roche Pharma (Schweiz) AG, Reinach, Switzerland.
 |
Assoc. Prof. Benny Sørensen, M.D., Ph.D.
Centre for Haemophilia and Thrombosis
Guy's and St. Thomas' NHS Foundation Trust and Kings College London School of Medicine, London, UK
|
Dr. Sørensen was educated in Professor Jörgen Ingersiev's Centre for Haemophilia and Thrombosis at the Aarhus University Hospital, Skejby, Denmark. In August 2008, he was appointed a Senior Clinical Research Fellow and Honorary Lecturer at the Centre for Haemophilia and Thrombosis at Guy's and St. Thomas' NHS Foundation Trust and Kings College London School of Medicine, London, UK, working as a co-ordinator and facilitator of a new Haemostasis Research Unit.
Dr. Sørensen's primary research interests include the study of patients with congenital and acquired bleeding disorders and individualising haemostatic intervention in patients, based on the recording of specific characteristics of whole blood clot formation. Special areas of interest also include patients suffering from severe haemophilia A with inhibitors to Factor VIII as well as the management of perioperative bleeding.
Since 2003, Dr. Sørensen has published and presented more than 60 original scientific publications. He is a board member and scientific secretary of the Danish Society of Thrombosis and Haemostasis, an invited reviewer for a number of International scientific journals and is a member of the editorial advisory board of the Journal of Thrombosis and Haemostasis.
Disclosure statement:
Dr Benny Sørensen has participated in advisory boards and/or
received speaker honorariums from Novo Nordisk, Baxter,
CSL Behring, Bayer, Pentapharm, Biovitrum. The
Haemostasis Research Unit receives unrestricted research
support from Novo Nordisk, Grifols, CSL Behring, LFB,
Baxter, Bayer, Octapharma.
 |
Assoc. Prof. Kenichi Tanaka, M.D.
Department of Anesthesiology
Emory University School of Medicine, Atlanta, U.S.A.
|
Dr. Tanaka is Associate Professor of Anaesthesiology, Emory University School of Medicine, and a member of Association of University Anesthesiologists (AUA). He serves on the Committee on Blood Management for American Society of Anesthesiologists (ASA), and the Research Committee of Society of Cardiovascular Anesthesiologists (SCA). His field of research includes clinical perioperative haemostatic management, anticoagulant therapy, antifibrinolytic therapy, thromboelastography/metry as well as in vitro and computer-based modelling of thrombin generation. He regularly serves as a reviewer for Anesthesia & Analgesia, and other peer-reviewed anaesthesiology and haematology journals.
Disclosure statement: Dr. Tanaka has disclosed that he has previously received honoraria as a speaker for Bayer, and CSL Behring, and has received research support from the following commercial organisations: Bayer, CSL Behring, Eagle, and Regado.
 |
Prof. Dr. Karim Brohi
Surgeon Trauma Clinical Academic Unit
The Royal London Hospital, London, UK
|
Dr. Brohi is Professor of Trauma Sciences at Barts and the London School of Medicine & Dentistry, and consultant in trauma & vascular surgery at The Royal London Hospital. He attended medical school at University College London and received training in London, Oxford, Cape Town and the San Francisco General Hospital. He leads active research programmes in basic, translational and clinical trauma science at Barts and the London Hospital and he has been engaged in collaborations throughout the world. A central interest of his includes coagulation and inflammation activation following injury, which is supported by a grant from the National Institute of Health Research. Brohi is the founder of the Trauma.org web site and Trauma-list email discussion group, which are both now in their 11th year of existence. He has lectured widely around the world and is committed to world-wide access to free, high quality education in trauma care.
Disclosure statement: Dr. Brohi received unrestricted research funding in terms of equipment and reagents from Pentapharm and Dynabyte.
.
Personalised CME certificates will be issued after passing the
multiple choice test.
for specific lectures indicates European CME credits (ECMEC) to be
earned from the European certifying
authority